Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Methods for the treatment of tinnitus induced by cochlear excitotoxicity

An excitatory and cochlear technology, applied in pharmaceutical formulations, organic active ingredients, medical preparations containing active ingredients, etc., can solve problems such as unreliable prediction of tinnitus and unclear molecular mechanism.

Inactive Publication Date: 2007-05-30
AURIS MEDICAL AG +1
View PDF13 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0014] Although there are some indications to support the hypothesis that NMDA receptors play an important role in cochlear excitotoxicity-induced tinnitus, the previous discussion suggests that the molecular mechanisms are unclear, and therefore, use of NMDA receptors cannot be reliably predicted. Are antagonists effective in blocking specific types of tinnitus?

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for the treatment of tinnitus induced by cochlear excitotoxicity
  • Methods for the treatment of tinnitus induced by cochlear excitotoxicity
  • Methods for the treatment of tinnitus induced by cochlear excitotoxicity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0058] Methods and materials

[0059] We study and test animal models of tinnitus caused by ototoxic excitotoxicity, which is caused by hearing damage. In general, tinnitus cannot be directly observed, because not all individuals’ hearing impairments cause tinnitus, and the sensation of tinnitus can be maintained for a few hours after the occurrence of excitotoxicity, or forever, this animal model The definition and implementation of this is a big challenge. For example, these things to consider include the need for more animals to obtain a sufficient number of tinnitus cases for research, and allowing tinnitus to be observed for a period of time. Because it is not clear whether tinnitus cases caused by cochlear excitotoxicity will continue, it is recommended to conduct research in the early stages of tinnitus.

[0060]The experiment was carried out in two stages. First, in the case of applying the therapeutic compound, the hearing loss after acute hearing loss and the appearance ...

Embodiment 2

[0086] Methods and materials

[0087] In order to evaluate the different mechanisms of tinnitus caused by salicylate and excitotoxicity, after the induction of these two different types of tinnitus, a comparative morphological analysis of the cochlear sensory nerve and Western Blot immunodetection (Western Blot immunodetection) were performed.

[0088] morphology

[0089] Two groups of Long Evans mice were used, 3 in each group. One group was intraperitoneally injected with a 350 mg / kg salicylic acid solution twice a day for 2 days; as in Example 1, the hearing of the other group was damaged. After the head of the deeply anesthetized rat was removed, the cochlea was removed from the temporal bone, and the cochlea was perfused with a fixative solution, which was 0.1M phosphate buffered saline (PBS), 2.5% glutaraldehyde, and pH 7.3. The cochlea is then processed, followed by scanning (SEM) processing or transmission electron microscopy (TEM) processing. For SEM, the auditory cartila...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to methods for the prevention and / or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and / or formulations for local administration to the inner ear. The tinnitus to be prevented and / or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence.

Description

Technical field [0001] The present invention relates to a method of delivering a drug mixture to the inner ear to treat tinnitus caused by cochlear excitotoxicity (cochlear excitotoxicity), and more specifically, to the N-methyl-D-aspartate (NMDA) Receptor antagonists are locally applied to the inner ear to inhibit the abnormal activity of the auditory nerve mediated by NMDA receptors after acute, repetitive or long-term or chronic cochlear excitotoxicity. The cochlear excitability is caused by auditory impairment and senility. Deafness, myocardial ischemia, hypoxia, treatment with one or more specific ototoxic drugs, and sudden deafness. Background technique [0002] Tinnitus, that is, feeling the sound without external sound stimulation, is a very common inner ear disorder. It is estimated that 8.6 million Americans suffer from chronic tinnitus, accounting for 3% of the American population (Centers for Disease Control and Prevention, Vital and Health Statistics, Series 10, #200...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/00A61K31/135A61K31/517A61K31/439A61K31/662A61K31/4535A61P27/16
CPCA61K31/135A61K31/4535A61K31/00A61K31/662A61K31/439A61K31/517A61P27/00A61P27/16A61P43/00A61K31/03A61K31/015
Inventor 马赛厄·吉顿吉恩-卢克·帕尔里米·普若尔
Owner AURIS MEDICAL AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com